Phase I Study of VLX-1005 in Healthy Subjects
NCT04783545
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
DRUG:
VLX-1005
DRUG:
Placebo
Sponsor
Veralox Therapeutics